LLY

779.86

-1.89%↓

JNJ

152.52

+0.03%↑

ABBV

185.27

-0.73%↓

NVO

68.23

+1.32%↑

UNH

307.35

+1.39%↑

LLY

779.86

-1.89%↓

JNJ

152.52

+0.03%↑

ABBV

185.27

-0.73%↓

NVO

68.23

+1.32%↑

UNH

307.35

+1.39%↑

LLY

779.86

-1.89%↓

JNJ

152.52

+0.03%↑

ABBV

185.27

-0.73%↓

NVO

68.23

+1.32%↑

UNH

307.35

+1.39%↑

LLY

779.86

-1.89%↓

JNJ

152.52

+0.03%↑

ABBV

185.27

-0.73%↓

NVO

68.23

+1.32%↑

UNH

307.35

+1.39%↑

LLY

779.86

-1.89%↓

JNJ

152.52

+0.03%↑

ABBV

185.27

-0.73%↓

NVO

68.23

+1.32%↑

UNH

307.35

+1.39%↑

Search

Arcutis Biotherapeutics Inc

Отворен

СекторЗдравеопазване

14 -1.89

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

13.63

Максимум

14.43

Ключови измерители

By Trading Economics

Приходи

-14M

-25M

Продажби

-5.5M

66M

EPS

-0.2

Марж на печалбата

-38.059

Служители

342

EBITDA

-14M

-19M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+46.1% upside

Дивиденти

By Dow Jones

Следващи печалби

13.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-169M

1.6B

Предишно отваряне

15.89

Предишно затваряне

14

Настроения в новините

By Acuity

50%

50%

154 / 380 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Arcutis Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

26.06.2025 г., 23:49 ч. UTC

Печалби

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26.06.2025 г., 22:19 ч. UTC

Придобивния, сливания и поглъщания

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26.06.2025 г., 21:30 ч. UTC

Печалби

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26.06.2025 г., 21:07 ч. UTC

Печалби

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26.06.2025 г., 23:49 ч. UTC

Пазарно говорене

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26.06.2025 г., 23:39 ч. UTC

Пазарно говорене

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26.06.2025 г., 23:34 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26.06.2025 г., 23:33 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26.06.2025 г., 23:32 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers Will No Longer Receive Earnings From BWP Management

26.06.2025 г., 23:32 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26.06.2025 г., 23:31 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26.06.2025 г., 23:31 ч. UTC

Придобивния, сливания и поглъщания

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26.06.2025 г., 23:30 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26.06.2025 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26.06.2025 г., 23:19 ч. UTC

Придобивния, сливания и поглъщания

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26.06.2025 г., 22:06 ч. UTC

Печалби

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26.06.2025 г., 21:15 ч. UTC

Печалби

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26.06.2025 г., 21:07 ч. UTC

Придобивния, сливания и поглъщания

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26.06.2025 г., 21:07 ч. UTC

Придобивния, сливания и поглъщания

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26.06.2025 г., 21:07 ч. UTC

Придобивния, сливания и поглъщания

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26.06.2025 г., 21:07 ч. UTC

Печалби

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26.06.2025 г., 21:06 ч. UTC

Придобивния, сливания и поглъщания

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26.06.2025 г., 21:06 ч. UTC

Придобивния, сливания и поглъщания

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26.06.2025 г., 21:06 ч. UTC

Пазарно говорене

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26.06.2025 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26.06.2025 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26.06.2025 г., 20:52 ч. UTC

Печалби

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26.06.2025 г., 20:51 ч. UTC

Печалби

Correct: Nike 4Q Net $211M, Not $200M >NKE

26.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

26.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Arcutis Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

46.1% нагоре

12-месечна прогноза

Среден 21.14 USD  46.1%

Висок 29 USD

Нисък 19 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcutis Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

7

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

12.42 / 14.93Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

154 / 380 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.